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trial. Country-speciﬁc unit costs data were obtained from national
sources. Costs are reported in 2007 euro. RESULTS: Iodixanol is
cost-effective compared to iohexol with both lower costs and
better effects related to fewer ADRs. For Germany, Italy, Spain,
Sweden, and UK, respectively, the mean per patient cost differ-
ences due to the reduction in ADRs were €444, €431, €574, €859,
and €753.CONCLUSIONS: Iodixanol results in fewer ADRs and
resulted in lower ADR costs per patient for this high risk patient
population across the ﬁve European countries.
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OBJECTIVES: To determine economic impact of Procoralan®
therapy in stable angina patients as compared to invasive PCI/
CABG therapy. METHODS: A cost-minimisation, probabilistic
model performed from a third party payer perspective in Poland.
Costs calculations were based on the National Health Fund rates.
Invasive therapy cost was assumed to be a weighted average of
PCI/CABG, according to Poland-speciﬁc proportions. Clinical
assumptions and risk proﬁles were derived from the Euro Heart
Survey. The economic impact was calculated for the patients not
qualiﬁed for invasive therapy or maintenance therapy with beta-
blocker due to contraindications or intolerance. Both one-way
(drug cost) and multi-way (revascularisation risk, reimbursement
level) sensitivity analyses were performed. RESULTS: The incre-
mental costs per patient per year were as follows: €747.82–743.34
for Procoralan® 5 mg/7.5 mg therapy respectively; € 3879.88 for
CABG, €2265.88 for PCI. The reduction in payer’s expenditure in
the range of €1918.32–1922.81 per patient per year was demon-
strated as a result of the application of Procoralan® 5 mg/7.5 mg
therapy instead of the invasive therapy. The obtained result applies
to the case of the whole Procoralan® price borne by the payer
(100% reimbursement). In the case of 70% and 50% reimburse-
ment rates savings amounted to €2112.09–2115.23 and
€2248.05–2250.20 depending on dose of the drug. The sensitivity
analyses results showed that change of the Procoralan® treatment
cost (+/-50%), wide range of changes in the risk of a secondary
revascularisation and the reimbursement level did not inﬂuence
the ultimate interpretation of the results. CONCLUSIONS: Third
party payer’s beneﬁts related to Procoralan® may apply to all
patients suffering from angina symptoms having contraindica-
tions or intolerance to beta-blocker. The greatest savings concern
patients not qualiﬁed for invasive therapy as no alternative treat-
ment is effective in this group, but in all scenarios the Procoralan®
therapy was proven to be cost-saving for public payer.
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OBJECTIVES: To compare the costs of induction of labor with
the costs of an expectant management strategy in women with
pregnancy-induced hypertension (PIH) or preeclampsia (PE) at
term. METHODS: The Hypertension and Preeclampsia Interven-
tion Trial At Term (HYPITAT) was a multicentre randomized
controlled clinical trial conducted in The Netherlands between
October 2005 and April 2008. Women diagnosed with PIH or PE
at 36 weeks of gestation were randomly allocated to either
induction of labor or expectant management. The study showed
that induction of labor reduced both maternal complications as
well as the caesarean section rate as compared to expectant
management. The economic analysis was performed from a soci-
etal perspective. Resource utilization was documented by speciﬁc
items in the Case Report Forms (CRF) and additional question-
naires. For most medical unit costs, we used estimates provided
by the ﬁnancial and economic departments of two participating
hospitals (one academic and one general hospital). For non-
medical costs and primary care costs Dutch standardized prices
were used. Sensitivity analyses were performed to explore the
impact of different assumptions and cost estimates on the results
of the costs analysis. RESULTS: Data of 756 women were ana-
lyzed. Mean costs per patient were €5400 for induction and
€6025 for expectant management (difference €625). This 10%
difference predominantly originated in the ante partum period:
per patient €977 for induction versus €1929 for expectant man-
agement. Comparable costs were found for delivery (€761 versus
€790 per patient). No substantial differences were found in the
post partum period. CONCLUSIONS: In women with PIH or PE
at term, costs associated with induction of labor are considerably
lower as compared to expectant management. This cost reduc-
tion is mainly due to differences in resource utilization in the ante
partum period.
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OBJECTIVES: To estimate the number and cost of cardiovascu-
lar (CV) events avoided over ﬁve years by treating with statins to
alternative low-density lipoprotein cholesterol (LDL-C) targets
of <3.0 mmol/L and <2.0 mmol/L, based on 1000 patients with
established cardiovascular disease (CVD) or diabetes from an
NHS perspective. METHODS: Proportional effects per mmol/L
LDL-C reduction for non-fatal myocardial infarction (MI), coro-
nary revascularisation and stroke were taken from a meta-
analysis of 14 randomised controlled trials of statin therapy.
Absolute risk reductions (ARR) between control and treatment
arms were calculated. Baseline LDL-C value of 3.6 mmol/L (SD
1.27) was taken from the Health Survey for England 2003 and
5000 LDL-C values 3.0 mmol/L and 2.0 mmol/L were ran-
domly generated from this distribution giving mean baseline
LDL-C values of 4.24 mmol/L and 3.86 mmol/L respectively.
Absolute LDL-C reductions needed to meet the alternative
targets were calculated and ARR in CV event incidence applied.
The % reduction in CV events for 1000 patients was used to
estimate number of CV events avoided; costs of events avoided
were calculated using the National Tariff 2007–08. RESULTS:
ARR between control and treatment arms was 1.8%, 1.8% and
0.6% for MI, coronary revascularisation and stroke respectively.
Absolute reduction required to meet the LDL-C target of
<3.0 mmol/L was 1.24 mmol/L resulting in 51 CV events
avoided (22 MIs; 22 CABG/PTCAs; 7 strokes), with a total cost
saving of £220,714 (MI = £70,158; CABG/PTCA = £130,368;
stroke = £20,188). The 1.86 mmol/L required to meet the LDL-C
target <2.0 mmol/L resulted in the 77 CV events avoided
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